Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/18459Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Papaioannides, D. | en |
| dc.contributor.author | Fotinou, M. | en |
| dc.contributor.author | Korantzopoulos, P. | en |
| dc.contributor.author | Latsi, P. | en |
| dc.contributor.author | Sinapidis, D. | en |
| dc.contributor.author | Akritidis, N. | en |
| dc.contributor.author | Orphanidou, D. | en |
| dc.date.accessioned | 2015-11-24T18:52:56Z | - |
| dc.date.available | 2015-11-24T18:52:56Z | - |
| dc.identifier.issn | 1234-1010 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/18459 | - |
| dc.rights | Default Licence | - |
| dc.subject | Antiviral Agents/*adverse effects | en |
| dc.subject | Female | en |
| dc.subject | Hepatitis C, Chronic/*drug therapy | en |
| dc.subject | Humans | en |
| dc.subject | Interferon-alpha/*adverse effects | en |
| dc.subject | Lung Diseases/diagnosis/*etiology | en |
| dc.subject | Middle Aged | en |
| dc.subject | Recombinant Proteins | en |
| dc.subject | Sarcoidosis/diagnosis/*etiology | en |
| dc.title | Sarcoidosis associated with interferon-alpha therapy for chronic hepatitis C | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/14704637 | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.publicationDate | 2004 | - |
| heal.abstract | BACKGROUND: Recombinant interferon-alpha (IFN-alpha ) is widely used for the treatment of chronic hepatitis C. Pulmonary side effects of IFN-alpha therapy seem to be rare. So far, only a few cases of sarcoidosis in association with IFN-alpha treatment of chronic hepatitis C have been CASE REPORT: A 52-year-old woman with chronic hepatitis C developed sarcoidosis during treatment with IFN-alpha. Diagnosis of sarcoidosis was based on chest imaging studies, the increased serum angiotensin converting enzyme levels, and the histology of a biopsied cervical lymph node. Spontaneous remission was observed following IFN-alpha withdrawal. CONCLUSIONS: Use of recombinant IFN-alpha in patients with chronic hepatitis C may trigger or contribute to the development of sarcoidosis in susceptible individuals. Patients should be monitored during and following IFN-alpha therapy for the occurrence of manifestations suggesting sarcoidosis. | en |
| heal.journalName | Med Sci Monit | en |
| heal.journalType | peer-reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ | |
Files in This Item:
There are no files associated with this item.
This item is licensed under a Creative Commons License
